Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Ratio (2021 - 2026)

Zentalis Pharmaceuticals has reported Equity Ratio over the past 6 years, most recently at 0.72 for Q1 2026.

  • For Q1 2026, Equity Ratio fell 6.15% year-over-year to 0.72; the TTM value through Mar 2026 reached 0.72, down 6.15%, while the annual FY2025 figure was 0.75, 4.51% down from the prior year.
  • Equity Ratio for Q1 2026 was 0.72 at Zentalis Pharmaceuticals, down from 0.75 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.84 in Q2 2023 and troughed at 0.72 in Q1 2026.
  • A 5-year average of 0.79 and a median of 0.79 in 2024 define the central range for Equity Ratio.
  • On a YoY basis, Equity Ratio climbed as much as 4.42% in 2024 and fell as far as 7.59% in 2024.
  • Year by year, Equity Ratio stood at 0.8 in 2022, then dropped by 1.51% to 0.79 in 2023, then fell by 1.15% to 0.78 in 2024, then fell by 4.51% to 0.75 in 2025, then dropped by 3.52% to 0.72 in 2026.
  • Business Quant data shows Equity Ratio for ZNTL at 0.72 in Q1 2026, 0.75 in Q4 2025, and 0.77 in Q3 2025.